Date: 2017-07-04

Type of information: Production agreement

Compound: tildrakizumab

Company: Sun Pharmaceutical Industries (India) Samsung BioLogics (Republic of Korea)

Therapeutic area:

Type agreement: manufacturing - bioproduction

Action mechanism:

  • monoclonal antibody. Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. In clinical studies for the treatment of chronic plaque psoriasis, tildrakizumab demonstrates efficacy in blocking inflammation by blocking IL-23. Other potential indications, which may be evaluated in future, include psoriatic arthritis and Crohn’s disease.
  • The drug has been initially developed by Merck&Co. In September 204, Merck & Co and Sun Pharmaceutical Industries have concluded a licensing agreement for tildrakizumab, (MK-3222).
  • In July 2016, Sun Pharma had announced a strategic licensing agreement with Almirall on the development and commercialization of tildrakizumab for psoriasis in Europe.


Details:     •  On July 4, 2017, Sun Pharmaceutical Industries and Samsung BioLogics announced a strategic long-term manufacturing agreement for tildrakizumab. The agreement was entered into by Sun Pharma’s wholly-owned subsidiary and Samsung BioLogics. According to the agreement, Sun Pharma has appointed Samsung BioLogics to manufacture this investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis.

Financial terms: The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential.

Latest news:

Is general: Yes